Bayer's Rally Faces Its Next Test: A Courtroom in Missouri
Published on 07/18/2026 at 06:13 | Redaktion boerse-global.de
Bayer’s stock has staged one of the most dramatic turnarounds in European pharmaceuticals, surging 72% over the past twelve months. The catalyst was a landmark Supreme Court ruling in late June that gutted thousands of “failure-to-warn” claims over glyphosate. But the very event that triggered the rally — a $7.25 billion class-action settlement — still lacks final court approval, and the hearing scheduled for early July has already been pushed back. For investors, the question is no longer whether the legal clouds are lifting, but whether the clearing skies are priced in.
The shift in sentiment has been stark. From a stock long viewed as a bet on litigation outcomes, Bayer now trades at €48.06, up nearly 30% since the start of the year and well above its 200-day moving average by roughly 26%. The technical picture suggests further room to run: the 52-week high of €53.86 remains about 12% above current levels, and the relative strength index still points to a market that isn’t yet overheating. Yet the rally has cooled in recent days, with the shares slipping 4.34% last week — a pullback many analysts view as a healthy breather rather than a reversal.
The Supreme Court’s 7-2 decision on June 25 established that federal law preempts state-level labeling requirements for crop-protection products. That ruling invalidates the core argument behind a wave of state-court cases, relieving Bayer of billions in potential liabilities. Already, the company has spent more than $10 billion on legal costs connected to the glyphosate saga. The court’s move, though, does not mark the end of the road. The $7.25 billion class-action settlement, announced in February and given preliminary approval, still requires a final fairness hearing before a federal judge in Missouri. That hearing was originally set for early July but has been delayed, with no new date yet announced.
Operationally, Bayer’s underlying business shows mixed signals. In the first quarter, group revenue rose 4.1% on a currency- and portfolio-adjusted basis to €13.405 billion, while EBITDA before special items climbed 9% to €4.453 billion. The Crop Science division drove much of the growth, with higher volumes and an uptick in margins. Yet glyphosate-specific sales slumped: herbicide revenue fell 10.2%, and glyphosate-based product lines dropped 15.1%, as North American and European customers delayed purchases. Management expects a partial recovery in the second half, particularly in Latin America.
Should investors sell immediately? Or is it worth buying Bayer?
The financial strain remains visible. Bayer posted a free cash flow deficit of €2.320 billion in the first quarter, largely due to €2.002 billion in net outflows from settling PCB and glyphosate claims. Net financial debt rose to €32.518 billion, up 9% from the end of 2025. For 2026, management has guided for negative free cash flow, as the settlement payments continue to weigh. Fitch affirmed Bayer’s BBB rating on July 13, 2026, but kept the outlook at “negative” — a downgrade from “stable” made in February that reflects the slow pace of deleveraging.
CEO Bill Anderson’s “Dynamic Shared Ownership” restructuring has trimmed costs and sped up decision-making, but the balance sheet remains a long-term project. The planned sale of the LARC business to Apollo for roughly €3 billion is one step toward shoring up capital. Still, the company’s ability to refinance and reduce debt hinges on the performance of newer pharmaceutical blockbusters such as Kerendia and Nubeqa, which will be in focus when Bayer reports half-year results on August 4.
Two key dates in August will shape the next leg of the story. The half-year report on August 4 will reveal whether drug sales can offset legal costs and glyphosate weakness. Then, on August 19, the Missouri court is expected to hold the final hearing on the $7.25 billion settlement. While preliminary approval was granted smoothly, the delay of the earlier hearing shows that the timeline cannot be taken for granted. Objections from plaintiffs or new procedural hurdles could still slow the process.
Alongside the settlement, Bayer has opened a second legal front: in late June, its Monsanto subsidiary filed antidumping and countervailing duty petitions against Chinese glyphosate imports with U.S. trade authorities. That petition is a response to persistent price pressure from Chinese competitors, and its outcome remains uncertain. The move signals that Bayer still sees glyphosate as a core product, despite the litigation risks of the past decade.
Bayer at a turning point? This analysis reveals what investors need to know now.
The market appears to be pricing in a clean resolution. The stock now sits 73% above where it traded a year ago, and the distance from its 200-day moving average suggests strong momentum. But the volatility remains high — single court announcements can swing the price sharply. If the Missouri hearing confirms the settlement without major objections, the rally could extend toward the 52-week high. If the process frays again, or if glyphosate volumes fail to recover, the downside could be just as rapid.
For now, Bayer is no longer seen as a distressed bet on legal luck. The question is whether the valuation already reflects the happy ending — or whether the real denouement is still to come.
Ad
Bayer Stock: New Analysis - 18 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
